Download the full-sized PDF of The Antidepressant/Antipanic/Neuroprotective Drug Phenelzine: Neuropharmacological and Drug Metabolism StudiesDownload the full-sized PDF



Permanent link (DOI):


Export to: EndNote  |  Zotero  |  Mendeley


This file is in the following communities:

Graduate Studies and Research, Faculty of


This file is in the following collections:

Theses and Dissertations

The Antidepressant/Antipanic/Neuroprotective Drug Phenelzine: Neuropharmacological and Drug Metabolism Studies Open Access


Other title
monoamine oxidase inhibitors
gamma-aminobutyric acid
phenylacetic acid
monoamine oxidase
drug metabolism
Type of item
Degree grantor
University of Alberta
Author or creator
Kumpula, David J
Supervisor and department
Baker, Glen (Psychiatry)
Examining committee member and department
Kerr, Bradley (Anesthesiology and Pain Medicine)
Fujiwara, Esther (Psychiatry)
Dursun, Serdar (Psychiatry)
Baker, Glen (Psychiatry)
Department of Psychiatry
Date accepted
Graduation date
Master of Science
Degree level
Phenelzine (PLZ) is a monoamine oxidase (MAO)-inhibiting antidepressant with anxiolytic and neuroprotective properties. Metabolites of PLZ were investigated in rat brain. Levels of phenylacetic acid (PAA) and β-phenylethylamine (PEA) were found to be elevated after administration of PLZ and PEH (a major metabolite of PLZ) to rats, but the effect was greater with PLZ in both cases. Acute administration of PLZ or PEH increased brain levels of alanine (ALA) and GABA and decreased glutamine (GLN) levels. When MAO was inhibited prior to PLZ administration, levels of GABA and ALA were not increased, supporting the idea that the metabolite PEH formed by MAO is responsible for the increases. Chronic PLZ administration significantly reduced weight gain in rats, and brain levels of amino acids were quite different after 1 and 3 weeks of PLZ administration, perhaps as a result of its decreased metabolism to PEH with time.
Permission is hereby granted to the University of Alberta Libraries to reproduce single copies of this thesis and to lend or sell such copies for private, scholarly or scientific research purposes only. Where the thesis is converted to, or otherwise made available in digital form, the University of Alberta will advise potential users of the thesis of these terms. The author reserves all other publication and other rights in association with the copyright in the thesis and, except as herein before provided, neither the thesis nor any substantial portion thereof may be printed or otherwise reproduced in any material form whatsoever without the author's prior written permission.
Citation for previous publication
Kumpula, D. J., Rauw, G., MacKenzie, E. M., Dursun, S. M. and Baker, G. B. (2010). 2- Phenylethylamine, 2-phenylethylidenehydrazine and phenylacetic acid as metabolites of phenelzine. Proc. Joint Meet. Can. Coll. Neuropsychopharmacol. and Can. Assoc. Neurosci., Ottawa, ONMacKenzie, E.M., Rauw, G., Kumpula, D. and Baker, G.B. (2010). Identification and quantification of beta-phenylethylidenehydrazine (PEH) as a metabolite of the MAO inhibitor phenelzine. Proc. 14th Bien. Int. Amine Oxidase Workshop, Edmonton, Alberta.Matveychuk, D., Mackenzie, E.G., Kumpula, D., Armstrong, I. and Baker, G.B. (2011). Comparison of the effects of the MAO inhibitor phenelzine and its metabolite PEH on brain levels of amino acids. Proc. 34th Ann. Meet. Can. Coll. Neuropsychopharmacol., Montreal, Quebec.

File Details

Date Uploaded
Date Modified
Audit Status
Audits have not yet been run on this file.
File format: pdf (Portable Document Format)
Mime type: application/pdf
File size: 1303820
Last modified: 2015:10:12 20:32:39-06:00
Filename: Kumpula_David_Spring 2013.pdf
Original checksum: bf8e25810a9825c25c989fdb2abd1b75
Well formed: true
Valid: true
File author: davidkumpula
Page count: 95
File language: en-CA
Activity of users you follow
User Activity Date